Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
Back to Home

Olatec Therapeutics

Private

Clinical-stage biotech developing oral NLRP3 inflammasome inhibitors, led by dapansutrile (OLT1177), which has advanced from discovery into later-stage clinical development across inflammatory and age-related diseases.

Company Info

Sector:Small Molecule Pharma
Headquarters:New York, New York, USA
Founded:2003
Funding Round:Series A
Total Funding:$40M

Funding & Investor Relations

Notable Investors

  • Sanders Morris Harris Group

Upcoming Milestones & Key Dates

2026-09-15
Clinical Milestone

Phase 2 DAPA-PD trial of dapansutrile in early Parkinson's disease enrolling patients

Clinical Development Pipeline

Dapansutrile (OLT1177)

Target: NLRP3 inflammasome
Parkinson's disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Damaris B. Skouras

Founder, Chairman and Chief Executive Officer

Caroline Williams-Gray, FRCP PhD

Clinical Advisory Board

David Haase, MD

Board of Directors and Clinical Advisory Board

Careers & Job Openings

See all open roles

Apply Now